Open AccessBortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance
Author(s) -
Kee Kiat Yeo,
Paul S. Gay,
Cecilia Fu,
Alan S. Wayne,
WeiZen Sun
Publication year - 2016
Publication title -
journal of pediatric hematology/oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.388
H-Index - 78
eISSN - 1536-3678
pISSN - 1077-4114
DOI - 10.1097/mph.0000000000000560
Subject(s) - medicine , mitoxantrone , regimen , prednisone , vincristine , vinorelbine , asparaginase , adverse effect , oncology , bortezomib , dexamethasone , chemotherapy , leukemia , multiple myeloma , cyclophosphamide , lymphoblastic leukemia , cisplatin
Children with relapsed acute lymphoblastic leukemia (ALL) typically receive vincristine-prednisone-L-asparaginase-doxorubicin reinduction chemotherapy similar to contemporary induction regimens. However, up to 20% of patients are unable to receive vincristine-prednisone-L-asparaginase-doxorubicin secondary to asparaginase intolerance. We report our experience with a promising reinduction regimen for children with relapsed ALL who are unable to receive asparaginase.